A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 1, 2016, Pages 51-59

  Scheller, Bruno ^a   Fontaine, Tobias ^a   Mangner, Norman ^b   Hoffmann, Stefan ^c   Bonaventura, Klaus ^d   Clever, Yvonne P ^a   Chamie, Daniel ^e   Costa, Ribamar ^e   Gershony, Gary ^f   Kelsch, Bettina ^g   Kutschera, Maren ^g   Généreux, Philippe ^h   Cremers, Bodo ^a   Böhm, Michael ^a   Speck, Ulrich ^g   Abizaid, Alexandre ^e  

^a SAARLAND UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^c Werner Forßmann Hospital   (Germany)

^d Ernst von Bergmann Klinikum   (Germany)

^e INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^f John Muir Hospital   (United States)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

Author keywords

balloon; drug coated eluting; interventional devices innovation; stent restenosis

Indexed keywords

ANTIOXIDANT; PACLITAXEL;

ADULT; AGED; ARTICLE; BALLOON CATHETER; BARE METAL STENT; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; CORONARY ARTERY; CORONARY ARTERY RECANALIZATION; DRUG ELUTING STENT; FEMALE; HEART CATHETERIZATION; HUMAN; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PTCA CATHETER; RANDOMIZED CONTROLLED TRIAL; SCORING BALLOON; TREATMENT OUTCOME;

EID: 84978839883     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26216     Document Type: Article

References (27)

1. Richardt G, Leschke M, Abdel-Wahab M, et al. Clinical outcomes of the resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from. A pooled analysis JACC Cardiovasc Interven 2013;6:905–913.
2. Kastrati A, Mehilli J, von Beckerath N, et al. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: A randomized controlled trial. Jama 2005;293:165–171.
3. Mehilli J, Byrne RA, Tiroch K, et al. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study. J Am Coll Cardiol 2010;55:710–6. 2-.
4. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113–2124.
5. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 2009;119:2986–2994.
6. Habara S, Mitsudo K, Kadota K, et al. Effectiveness of paclitaxel-eluting balloon catheter in patients with sirolimus-eluting stent restenosis. JACC Cardiovasc Intervention 2011;4:149–154.
7. Rittger H, Brachmann J, Sinha AM, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: The PEPCAD-DES study. J Am Coll Cardiol 2012;59:1377–1382.
8. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): A randomised, open-label trial. Lancet 2013;381:461–467.
9. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
10. Takano M, Yamamoto M, Murakami D, et al. Optical coherence tomography after new scoring balloon angioplasty for in-stent restenosis and de novo coronary lesions. Int J Cardiol 2010;141:e51–3.
11. Cremers B, Schmitmeier S, Clever YP, et al. Inhibition of neo-intimal hyperplasia in porcine coronary arteries utilizing a novel paclitaxel-coated scoring balloon catheter. Catheter Cardiovasc Interv 2014;84:1089–1098.
12. Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810–814.
13. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344–2351.
14. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773–781.
15. Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689–699.
16. Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: Paclitaxel-coated versus uncoated balloon: Femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358–1365.
17. Unverdorben M, Kleber FX, Heuer H, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2010;99:165–174.
18. Mathey DG, Wendig I, Boxberger M, et al. Treatment of bifurcation lesions with a drug-eluting balloon: The PEPCAD V (Paclitaxel Eluting PTCA Balloon in Coronary Artery Disease) trial. EuroIntervention 2011;7 Suppl K:K61–K65.
19. Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries restenosis rate and clinical outcome. J Am Coll Cardiol 2011;58:1105–1109.
20. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: The BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012;60:2473–2480.
21. Speck U, Cremers B, Kelsch B, et al. Do pharmacokinetics explain persistent restenosis inhibition by a single dose of paclitaxel?. Circ Cardiovasc Interv 2012;5:392–400.
22. Fonseca A, Costa Jde R Jr, Abizaid A, et al. Intravascular ultrasound assessment of the novel AngioSculpt scoring balloon catheter for the treatment of complex coronary lesions. J Invasive Cardiol 2008;20:21–27.
23. de Ribamar Costa J Jr, Mintz GS, Carlier SG, et al. Nonrandomized comparison of coronary stenting under intravascular ultrasound guidance of direct stenting without predilation versus conventional predilation with a semi-compliant balloon versus predilation with a new scoring balloon. Am J Cardiol 2007;100:812–817.
24. Scheinert D, Peeters P, Bosiers M, et al. Results of the multicenter first-in-man study of a novel scoring balloon catheter for the treatment of infra-popliteal peripheral arterial disease. Catheter Cardiovasc Interv 2007;70:1034–1039.
25. Bosiers M, Deloose K, Cagiannos C, et al. Use of the AngioSculpt scoring balloon for infrapopliteal lesions in patients with critical limb ischemia: 1-year outcome. Vascular 2009;17:29–35.
26. Suzuki K. Anti-oxidants for therapeutic use: Why are only a few drugs in clinical use? Adv Drug Deliv Rev 2009;61:287–289.
27. Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. JACC Cardiovasc Interv 2012;5:323–330.